Todays announcement is truly fabulous.These PC results illustrate Zantrenes potential to enhance AND compliment the anti-melanoma immune response.
PD-1 inhibitors created a paradigm shift in cancer immunotherapy.
When I think PD-1 inhibitors Keytruda (Merck) and Opdivo (Bristol Myers) spring to mind. If Zantrene synergises to overcome checkpoint inhibitor resistance and Keytruda success rate in patients is only ~ 15%. How many billions is Zantrene potentially worth to a company like Merck if their 15% success rate could be improved even by only 10-20% ?
Can't wait to watch how this all plays out the next 18 months !
Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-39
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.030(1.63%) |
Mkt cap ! $307.6M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.94 | $1.77 | $230.8K | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15405 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.85 | 1750 | 1 |
View Market Depth
| Last trade - 16.10pm 25/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |